PETALING JAYA: A contract that was renewed by the government and accepted by Duopharma Biotech Bhd
is expected to contribute to about a quarter of the company’s revenue in the financial year 2023.
In a report yesterday, TA Research said it is mildly positive on the contract extension for the pharmaceutical company.
The contract extends until June 30, 2023 for the company to supply pharmaceutical products and non-pharmaceutical products to hospitals, clinics and others under the government’s Approved Product Purchase List (APPL).
...